Debunking the notion that boosters don't reduce Omicron symptomatic infections. Another new study from Qatar shows they are halved medrxiv.org/content/10.110… matched >400,000 people with mRNA vaccines 2 vs 3-dose
Booster vaccine effectiveness vs Omicron infections 62% (2 dose 32%) @UKHSA in people without Prior Covid assets.publishing.service.gov.uk/government/upl…
and higher with Prior Covid, hybrid immunity, as seen in all studies
Since the booster protection vs Delta symptomatic infections was 95% and vs Omicron it is ~50%, that is a 10-fold increase in breakthroughs
Which is why there is the misperception that there is no booster protection from infections or transmission w/ Omicron
*when there is*
They are cut in half; 90% vs hospitalizations
I watched @billmaher and @bariweiss last night @RealTimers and it is so obvious they are not in touch with the data and, unfortunately, propagating misinformation
Adding this important study, the largest household (~12,000) contact study for Omicron and Delta infections and *impact of booster* (3rd) dose vaccination:
Infections were reduced OR 0.54, CI 0.40-0.71)
Transmission risk reduced OR: 0.72, CI: 0.56-0.92) medrxiv.org/content/10.110…
First post of this thread, Figure label correction by authors (Moderna, panel B, not Pfizer in both panels)
And full discussion of these findings erictopol.substack.com/p/where-do-we-…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
New CDC genomic data shows continued rise of the KP.3 variant that accounts for 1 of 3 Covid cases.
LB.1 is gaining, too, as JN.1 fades away
This variant growth advantage plot by @BenjMurrell (H/T @siamosolocani) shows why this is the case. Note KP.3 is the one at far left w/ almost 3-fold advantage to JN.1.
Reinforces why the decision to develop the KP.2 vaccine booster (instead of JN.1) was a good one
Spike mutation map to show the differences betweem KP.3 and JN.1 (and LB.1, KP.2)
The connection between #SARSCoV2 and neurodegeneration
@TheLancetNeuro
Quotes below: 1. SARS-CoV-2 infection should be considered as a risk factor for Alzheimer’s disease, even though the distinction between causation versus disease acceleration is not clear.thelancet.com/journals/laneu…
2. Inflammation in patients with COVID-19, and controlled experiments show prolonged neuro-inflammation after mild SARS-CoV-2 infection
in macaques.
3. A direct correlation has been reported
between prior SARS-CoV-2 infection and increased risk
of Alzheimer’s disease (figure).
4. So far, the estimated lifetime cumulative risk of dementia due to hospitalisation for any viral infection is 1·48 (95% CI 1·15–1·91).
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good.
My oped on the JN.1 variant and the 2nd biggest US wave of infections (after Omicron) since the pandemic began
@latimes @latimesopinion #LongCovid latimes.com/opinion/story/…
Recent @CDCgov #SARSCoV2 wastewater data for current wave (vs Omicron Jan 2022 and subsequent waves), graph by @luckytran
Sorry, @washingtonpost, but this is not "another Covid-19 uptick" as you put it in your Health Alert. You ignore the best metric for infections that we have at present—wastewater—focusing only on hospitalizations washingtonpost.com/health/2024/01…
3 New #LongCovid reports 1. Vaccination protection—1 dose 21%, 2 doses 59%, 3 doses 73% among ~590,000 people in Sweden (strong association) bmj.com/content/383/bm…
2. 3-year prospective follow up of a cohort of ~1350 participants, hospitalized in China
—Lung function restored back to baseline in most
—Higher risk of reinfection that people w/o Long Covid
—Half w/ persistent symptoms thelancet.com/journals/lanre…
3. At @RSNA annual meeting, brain MRI with microstructure imaging (DMI), participants with #LongCovid vs controls had microstructure changes associated with impaired cognition, sense of smell and fatigue eurekalert.org/news-releases/…